Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Stella acts as an intermediary. Researcher contact info is never exposed.